Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18
Author: Villa, LL
Ault, KA
Giuliano, AR
Costa, RLR
Petta, CA
Andrade, RP
Brown, DR
Ferenczy, A
Harper, DM
Koutsky, LA
Kurman, RJ
Lehtinen, M
Malm, C
Olsson, SE
Ronnett, BM
Skjeldestad, FE
Steinwall, M
Stoler, MH
Wheeler, CM
Taddeo, FJ
Yu, J
Lupinacci, L
Railkar, R
Marchese, R
Esser, MT
Bryan, J
Jansen, KU
Sings, HL
Tamms, GM
Saah, AJ
Barr, E
Abstract: Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naive and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were similar to 12- to 26-fold higher than those observed in baseline-naive women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported. (c) 2006 Elsevier Ltd. All rights reserved.
Subject: human papillomavirus
Country: Inglaterra
Editor: Elsevier Sci Ltd
Citation: Vaccine. Elsevier Sci Ltd, v. 24, n. 27-28, n. 5571, n. 5583, 2006.
Rights: fechado
Identifier DOI: 10.1016/j.vaccine.2006.04.068
Date Issue: 2006
Appears in Collections:Unicamp - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
WOS000238859700005.pdf442.01 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.